A seven-year-old girl walked onto a Hollywood stage this month and told the world she can see stars now.

The science story that deserved far more than a red carpet moment

Her name is Hannah Reif. She was born with Leber congenital amaurosis — a rare inherited retinal disease that strips children of their sight, usually completely, by early adulthood. Then a gene therapy called Luxturna changed everything for her.

I think we are living through one of the most consequential moments in the history of medicine, and the discourse around it is embarrassingly thin. On April 18, 2026, the Breakthrough Prize Foundation awarded a $3 million prize to Jean Bennett, Katherine High, and Albert Maguire — the three scientists who built the first FDA-approved gene therapy for any inherited disease. The ceremony was in Santa Monica. James Corden hosted. Ben Affleck was in the audience.

The celebrities got the headlines. The scientists should have.

Here is what actually happened, stripped of the glamour. Bennett and Maguire met in medical school in the 1980s and started dreaming about replacing faulty genes in the retina — at a time when that was, in their own words, like thinking you could go to the moon in 1950.

They spent a decade at Penn's Scheie Eye Institute working on mice, then on blind dogs with the same RPE65 gene mutation that causes LCA in humans. In July 2000, they injected the therapy into one eye of three dogs and left a fourth untreated as a control. Within a week, the treated dogs were running obstacle courses without bumping into anything.

From blind puppies to a Hollywood stage: the long road to proof

I remember reading about early gene therapy trials in the early 2000s and thinking the field was cursed. After 18-year-old Jesse Gelsinger died in a 1999 trial, investors fled and the whole enterprise nearly collapsed.

Bennett, Maguire, and Katherine High at Children's Hospital of Philadelphia kept going anyway. High joined the collaboration in 2005 and brought the regulatory and manufacturing expertise needed to actually get a drug approved. The three of them designed the pivotal clinical trial together, including a novel endpoint to measure whether the therapy was actually working in living patients.

In December 2017, Luxturna became the first FDA-approved gene therapy for a genetic disease in the United States. The therapy works by injecting a functional copy of the RPE65 gene directly into the retina using a modified, harmless virus as a delivery vehicle. It is a one-time treatment. Patients treated over a decade ago are still maintaining stable vision improvements.

“Starting blind, and then seeing their children's faces, and being able to go to school and read the whiteboards and read books and stuff like that.”

— Jean Bennett, 2026 Breakthrough Prize Laureate, The Harvard Crimson

That quote is not a press release. That is a scientist describing what her life's work actually produced.

The legal architecture that made this possible — and what it still gets wrong

Here is where I want to push back on the triumphalism a little, because the law around gene therapy is still a mess. Luxturna was listed at $425,000 per eye when it was approved. That is not a typo. The full treatment costs roughly $850,000 for both eyes, and in 2025 total sales were only about $50 million — meaning most eligible patients globally still cannot access it.

Some will argue that the price reflects the cost of decades of research and the small patient population. I do not buy that argument as a full defense. The foundational research was funded in large part by public money and nonprofit grants, including roughly $10 million from the Foundation Fighting Blindness. When public investment produces a breakthrough, pricing it out of reach for most of the world is a policy failure, not just a market outcome.

The good news — and it is genuinely good — is that Luxturna blazed a legal and regulatory trail that others are now running down fast. Their work has opened the door to more than 140 gene therapy trials for retinal conditions including macular degeneration and diabetic retinopathy, diseases that collectively affect about 30 million people in the US alone.

What the prize actually signals about where science is heading

The 2026 Breakthrough Prize was not just about one therapy. Stuart Orkin and Swee Lay Thein also won for work that led to gene-editing therapies for sickle cell disease and beta-thalassemia. Rosa Rademakers and Bryan Traynor were recognized for discovering the most common genetic cause of ALS.

This is what a genuine scientific revolution looks like from the inside. Not a single eureka moment, but decades of unglamorous work, regulatory battles, failed funding rounds, and a husband-and-wife team who adopted the blind dogs they cured.

The law has a role to play in whether this revolution reaches everyone or just the wealthy. The FDA approval framework for gene therapies is genuinely smart policy — it is rigorous without being obstructionist. But the pricing and access side of the equation is still broken, and no amount of Hollywood galas changes that.

Would you trust a healthcare system that can cure your child's blindness but only if you can afford a house in cash?